BSE filing, NSE: VENMAX. Summary written from the filing by ALFA Finder's alert engine.
Venmax Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹13.00
- Market cap
- ₹11.42 Cr
- Revenue (annual)
- ₹8.02 Cr
- Net profit (annual)
- ₹0.25 Cr
- P/E (TTM)
- 40.7×Sector 46.5×
- Promoter holding
- 10.46%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venmax Drugs & Pharmaceuticals Ltd
All →Venmax Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the quarter ended September 30, 2026.
Venmax Drugs & Pharmaceuticals Annual General Meeting
Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.
Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.
Venmax Drugs & Pharmaceuticals Acquisition
NCLT Hyderabad directed Venmax to convene a shareholder meeting on 24 Oct 2026 for the amalgamation of Hatri Pharma into Venmax. The order also dispensed with meetings of Hatri Pharma's shareholders and creditors.
Venmax Drugs & Pharmaceuticals Annual Report
Venmax Drugs and Pharmaceuticals Limited has submitted its Annual Report for the Financial Year 2025-26, including the Notice for its 37th Annual General Meeting.
Venmax Drugs & Pharmaceuticals Board Meeting Outcome
Venmax Drugs held a board meeting to approve the Directors' Report, AGM date, and appoint/regularize key directors. The meeting outcomes were disclosed under Regulation 30.
Other acquisition announcements
All →Emkay Global Financial Services Acquisition Worth ₹21.38 Cr
Emkay Capital, a subsidiary, will acquire Emkay Investment Managers for Rs.21.38 Crore cash. The related-party deal is at arm's length and payable in tranches.
- Value
- ₹21.38 Cr
- Execution
- 90 days
TVS Motor Company Acquisition Worth ₹25,000 Cr
TVS Motor will acquire 100% of Harita ARC Limited, a related-party shell, for a stated Rs 25,000 Crore. It supports the proposed consumer finance demerger.
- Value
- ₹25,000 Cr
Rite Zone Chemcon India Acquisition Worth ₹4.97 Cr
Rite Zone Chemcon's board approved acquiring 51% of Cleanux Green Solution via share swap for about INR 4.97 Crore. The board also approved preferential issues and an EGM on 23 November 2026.
- Value
- ₹4.97 Cr
eClerx Services Acquisition Worth ₹15.57 Cr
eClerx's board approved buying about 2% of Personiv Eclipse Inc. from its wholly owned subsidiary eClerx LLC for USD 1.64 million. The intra-group transfer adds no change to aggregate ownership.
- Value
- ₹15.57 Cr
- Execution
- 1 Month
Fortis Healthcare Acquisition Worth ₹277 Cr
Fortis Healthcare's wholly-owned subsidiary IHL acquired Suguna Hospital's business and land in Bengaluru via slump sale. The cumulative consideration is approximately INR 277 Crore, consummated today.
- Value
- ₹277.0 Cr
Authum Investment & Infrastructure Acquisition
NCLT approved the consortium resolution plan for A A Estates Private Limited, with Authum as a resolution applicant. No consideration amount is disclosed.